Hematologic Diseases Clinical Trial
Official title:
Effect of Dose Fractionation of Testosterone Cypionate on Hematocrit in Transgender Men With Erythrocytosis Secondary to Testosterone Use.
A transgender man is someone with a male identity who were born with a vulva and vagina. The acquisition of masculine characters can come from surgery or from the use of testosterone. Despite the benefit of using this hormone in relation to hair development, muscle mass gain and changes in voice timbre, its use can cause an increase in the hematocrit (Ht) level. When erythrocytosis occurs (Ht ≥ 50%), the currently proposed conduct is the suspension of cross-hormonization for 3 months, which has negative effects on the affirmation process. This project aims to assess whether reducing the dose of testosterone cypionate by half (100mg/15d) can mitigate the negative outcomes caused by the suspension with the benefit of reducing the hematocrit level in trans patients who developed erythrocytosis using testosterone. This is a pilot study that will compare the intervention (testosterone cypionate 100 mg, fortnightly) to the suspension of the drug, both for 3 months, with the main outcome being the hematocrit level. Hormonal and biochemical levels and the Hospital Anxiety and Depression scale (HAD) will also be evaluated in patients treated at the Gender Incongruence Outpatient Clinic of the Hospital das Clínicas of the Faculty of Medicine of Ribeirão Preto.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04094844 -
Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation
|
N/A | |
| Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
| Recruiting |
NCT03918343 -
Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT01445561 -
Ultra Low Dose Interleukin-2 in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT06148610 -
Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
|
||
| Completed |
NCT04168983 -
Impact of Sophrology on the Pain Felt During a Bone Marrow Aspiration and Biopsy
|
N/A | |
| Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
| Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
| Completed |
NCT01108159 -
Integrated Whole-Genome Analysis of Hematologic Disorders
|
||
| Completed |
NCT00800839 -
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
|
Phase 2 | |
| Completed |
NCT00213239 -
A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children
|
Phase 1/Phase 2 | |
| Terminated |
NCT00208949 -
A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF
|
Phase 2 | |
| Terminated |
NCT00176826 -
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
|
Phase 2/Phase 3 | |
| Completed |
NCT00208962 -
Allogeneic Cell Therapy for Adults With Hematologic Malignancies
|
Phase 2 | |
| Completed |
NCT00000603 -
Cord Blood Stem Cell Transplantation Study (COBLT)
|
Phase 2 | |
| Completed |
NCT00000587 -
Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection
|
Phase 2 | |
| Active, not recruiting |
NCT03655678 -
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia
|
Phase 2/Phase 3 | |
| Completed |
NCT03611257 -
Effect of dRAST on Treatment for Bacteremia in Patients With Hematologic Diseases
|
N/A | |
| Completed |
NCT02827149 -
High Resolution Donor Recipient HLA Matching Level in Unrelated HSCT
|
||
| Completed |
NCT04584528 -
Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease
|
N/A |